Nasal Spray Composition for Longer-Lasting Rhinitis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nasal compositions for treating acute and allergic rhinitis, such as Respibien, provide only temporary relief and are limited in efficacy due to the unpredictability of effects from combining multiple active ingredients, requiring extensive animal experiments and clinical trials to determine optimal ratios and dosages.
Innovation Solution
A nasal composition containing specific amounts of chlorpheniramine maleate (200 to 1000 mg) and oxymetazoline hydrochloride (10 to 100 mg) administered once or twice a day, providing long-lasting and safe relief for sneezing, rhinorrhea, and nasal blockage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple active ingredients are combined in nasal compositions, then therapeutic efficacy is improved, but predicting the specific effects and optimal ratios becomes extremely difficult
Solution Approach 1:
The patent applies parameter changes by establishing specific concentration ranges for each active ingredient (chlorpheniramine maleate: 0.1-1.0%, oxymetazoline hydrochloride: 0.01-0.1%, xylometazoline hydrochloride: 0.03-0.3%) to optimize therapeutic efficacy. This systematic variation of concentration parameters resolves the contradiction by providing predictable, effective combinations without requiring extensive trial-and-error experimentation.
Solution Approach 2:
The patent employs composite materials by formulating a nasal composition containing multiple active ingredients (antihistamine, vasoconstrictor, and optionally corticosteroid) in specific ratios. This composite approach achieves superior therapeutic effects that cannot be obtained with single ingredients, while the defined concentration ranges make the composition predictable and manufacturable.
2Measurement precision
If extensive animal experiments and clinical trials are conducted to determine optimal ratios and dosages, then prediction accuracy is improved, but time and cost increase significantly
Solution Approach 1:
The patent applies preliminary action by establishing optimal concentration ranges through prior research and development before commercialization. The specific ratios of active ingredients were determined in advance through systematic studies, allowing the product to be manufactured and marketed without requiring extensive additional animal experiments or clinical trials for each batch.
Solution Approach 2:
The patent effectively copies successful formulation strategies from established nasal medications while adapting specific concentration ranges. By referencing proven active ingredient combinations and their therapeutic effects, the inventors were able to predict effective ratios without conducting exhaustive new experiments, thereby reducing time and cost.
3Ease of operation
If existing nasal compositions are used, then immediate relief is provided, but the relief is only temporary and efficacy is limited
Solution Approach 1:
The patent merges multiple therapeutic mechanisms by combining an antihistamine (chlorpheniramine maleate) that addresses sneezing and rhinorrhea with a vasoconstrictor (oxymetazoline hydrochloride or xylometazoline hydrochloride) that addresses nasal blockage. This combination provides comprehensive relief for all major nasal symptoms simultaneously, extending the duration and effectiveness of treatment compared to single-ingredient formulations.
Solution Approach 2:
The nasal composition achieves multi-functionality by treating multiple symptoms (sneezing, rhinorrhea, and nasal blockage) with a single formulation. The combination of active ingredients provides universal relief for various nasal symptoms caused by different mechanisms, making the treatment more durable and effective than single-purpose medications.
Data Source
AI summary
The purpose of the present invention is to provide: a composition for treating acute rhinitis and allergic rhinitis; and a method for treating acute rhinitis and allergic rhinitis. Specifically, the present invention pertains to a composition that comprises, per 100 mL of the composition, chlorpheniramine or a pharmaceutically acceptable salt thereof in an amount of 200-1000 mg as expressed in terms of chlorpheniramine maleate, and oxymetazoline or a pharmaceutically acceptable salt thereof in an amount of 10-100 mg as expressed in terms of oxymetazoline hydrochloride; and a method for treating acute rhinitis and allergic rhinitis by spraying the composition into a nostril once a day or twice a per day at an interval of 10 hours or more.